rs12140361 - SDHC
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer - Unknown journal (n.d.) · Unknown authors · PubMed 29367611
ABSTRACT: Identifying single nucleotide polymorphisms (SNPs) that influence chemotherapy disposition may help to personalize cancer treatment and limit toxicity. Genome-wide approaches are unbiased, compared with candidate gene studies, but usually require large cohorts. As most chemotherapy is given cyclically multiple blood sampling is required to adequately define drug disposition, limiting patient recruitment. We found that carboplatin and paclitaxel disposition are stable phenotypes in ovarian cancer patients and tested a genome-wide association study (GWAS) design to identify SNPs associated with chemotherapy disposition. We found highly significant SNPs in ABCC2, a known carboplatin transporter, associated with carboplatin clearance (asymptotic P = 5.2 × 106, empirical P
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Drug interactions
-
paclitaxel dosing in epithelial ovarian cancer Moderate
rs12140361 is associated with paclitaxel disposition in epithelial ovarian cancer patients
if diagnosed with epithelial ovarian cancer and considering paclitaxel, discuss this variant with your oncologist